In the Media

Ed Silverman writes for The Wall Street Journal about a new MIT study showing that drug development costs are outweighing profitability. “There has been a lot of focus on the risk of R&D and bringing a drug to market, but not really on what happens to drugs once they are on the market,” explains Prof. Ernst Berndt.